Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.
Identifieur interne : 001121 ( Main/Exploration ); précédent : 001120; suivant : 001122Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.
Auteurs : Ciro Romano [Italie] ; Andrea Del Mastro [Italie] ; Ausilia Sellitto [Italie] ; Eleonora Solaro [Italie] ; Sergio Esposito [Italie] ; Giovanna Cuomo [Italie]Source :
- Clinical rheumatology [ 1434-9949 ] ; 2018.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps monoclonaux humanisés (pharmacologie), Anticorps monoclonaux humanisés (usage thérapeutique), Complément C3 (métabolisme), Complément C4 (métabolisme), Femelle, Humains, Jeune adulte, Mâle, Polyarthrite rhumatoïde (sang), Polyarthrite rhumatoïde (traitement médicamenteux), Sujet âgé, Études rétrospectives.
- MESH :
- métabolisme : Complément C3, Complément C4.
- pharmacologie : Anticorps monoclonaux humanisés.
- sang : Polyarthrite rhumatoïde.
- traitement médicamenteux : Polyarthrite rhumatoïde.
- usage thérapeutique : Anticorps monoclonaux humanisés.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Jeune adulte, Mâle, Sujet âgé, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Monoclonal, Humanized (pharmacology), Antibodies, Monoclonal, Humanized (therapeutic use), Arthritis, Rheumatoid (blood), Arthritis, Rheumatoid (drug therapy), Complement C3 (metabolism), Complement C4 (metabolism), Female, Humans, Male, Middle Aged, Retrospective Studies, Young Adult.
- MESH :
- chemical , metabolism : Complement C3, Complement C4.
- chemical , pharmacology : Antibodies, Monoclonal, Humanized.
- chemical , therapeutic use : Antibodies, Monoclonal, Humanized.
- blood : Arthritis, Rheumatoid.
- drug therapy : Arthritis, Rheumatoid.
- Adult, Aged, Female, Humans, Male, Middle Aged, Retrospective Studies, Young Adult.
Abstract
Tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, is known to be able to rapidly reduce acute phase reactants. Although complement components are part of the acute phase, no data are available on a possible effect of tocilizumab on complement proteins. Serum levels of complement components C3 and C4 were retrospectively assessed in 19 consecutive rheumatoid arthritis patients eligible for tocilizumab treatment. Tocilizumab was found to reduce all known acute phase reactants, including C3 and C4 levels. C3 and C4 were found to decrease as early as 4 weeks after the first tocilizumab infusion. On average, C3 decreased by 24.02, 27.35, 33.62, and 32.81%, as compared to pre-treatment values, after 1, 3, 6, and 12 months of therapy, respectively; likewise, C4 decreased by 44.74, 43.40, 54.33, and 54.56% at the same time points with respect to pre-treatment values. A discrete proportion of patients (38.46 and 30.76% for C3 and C4, respectively) displayed subnormal complement serum levels early (4 weeks) after initiation of tocilizumab treatment, which raised suspicion for complement consumption. However, no circulating immunocomplexes were found nor did any patient ever display clinical features of immunocomplex disease during a median follow-up of 38 months. After 12 months of therapy, 68.75 and 56.25% of patients had abnormally low C3 and C4 serum levels, respectively. Reduction in C3 and C4 serum levels should be included among the anti-inflammatory effects exerted by tocilizumab and are thus to be considered as an expected outcome of the mechanism of action of this drug.
DOI: 10.1007/s10067-018-3992-7
PubMed: 29362962
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000872
- to stream PubMed, to step Curation: 000872
- to stream PubMed, to step Checkpoint: 000632
- to stream Ncbi, to step Merge: 001918
- to stream Ncbi, to step Curation: 001918
- to stream Ncbi, to step Checkpoint: 001918
- to stream Main, to step Merge: 001120
- to stream Main, to step Curation: 001121
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.</title><author><name sortKey="Romano, Ciro" sort="Romano, Ciro" uniqKey="Romano C" first="Ciro" last="Romano">Ciro Romano</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples, Italy. ciro.romano@unicampania.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Del Mastro, Andrea" sort="Del Mastro, Andrea" uniqKey="Del Mastro A" first="Andrea" last="Del Mastro">Andrea Del Mastro</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Ospedale del Mare, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Ospedale del Mare, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Sellitto, Ausilia" sort="Sellitto, Ausilia" uniqKey="Sellitto A" first="Ausilia" last="Sellitto">Ausilia Sellitto</name><affiliation wicri:level="1"><nlm:affiliation>"S. Carlo" Regional Hospital, Potenza, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>"S. Carlo" Regional Hospital, Potenza</wicri:regionArea><wicri:noRegion>Potenza</wicri:noRegion></affiliation></author><author><name sortKey="Solaro, Eleonora" sort="Solaro, Eleonora" uniqKey="Solaro E" first="Eleonora" last="Solaro">Eleonora Solaro</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Esposito, Sergio" sort="Esposito, Sergio" uniqKey="Esposito S" first="Sergio" last="Esposito">Sergio Esposito</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Cuomo, Giovanna" sort="Cuomo, Giovanna" uniqKey="Cuomo G" first="Giovanna" last="Cuomo">Giovanna Cuomo</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29362962</idno><idno type="pmid">29362962</idno><idno type="doi">10.1007/s10067-018-3992-7</idno><idno type="wicri:Area/PubMed/Corpus">000872</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000872</idno><idno type="wicri:Area/PubMed/Curation">000872</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000872</idno><idno type="wicri:Area/PubMed/Checkpoint">000632</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000632</idno><idno type="wicri:Area/Ncbi/Merge">001918</idno><idno type="wicri:Area/Ncbi/Curation">001918</idno><idno type="wicri:Area/Ncbi/Checkpoint">001918</idno><idno type="wicri:Area/Main/Merge">001120</idno><idno type="wicri:Area/Main/Curation">001121</idno><idno type="wicri:Area/Main/Exploration">001121</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.</title><author><name sortKey="Romano, Ciro" sort="Romano, Ciro" uniqKey="Romano C" first="Ciro" last="Romano">Ciro Romano</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples, Italy. ciro.romano@unicampania.it.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Del Mastro, Andrea" sort="Del Mastro, Andrea" uniqKey="Del Mastro A" first="Andrea" last="Del Mastro">Andrea Del Mastro</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Ospedale del Mare, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Ospedale del Mare, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Sellitto, Ausilia" sort="Sellitto, Ausilia" uniqKey="Sellitto A" first="Ausilia" last="Sellitto">Ausilia Sellitto</name><affiliation wicri:level="1"><nlm:affiliation>"S. Carlo" Regional Hospital, Potenza, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>"S. Carlo" Regional Hospital, Potenza</wicri:regionArea><wicri:noRegion>Potenza</wicri:noRegion></affiliation></author><author><name sortKey="Solaro, Eleonora" sort="Solaro, Eleonora" uniqKey="Solaro E" first="Eleonora" last="Solaro">Eleonora Solaro</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Esposito, Sergio" sort="Esposito, Sergio" uniqKey="Esposito S" first="Sergio" last="Esposito">Sergio Esposito</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author><author><name sortKey="Cuomo, Giovanna" sort="Cuomo, Giovanna" uniqKey="Cuomo G" first="Giovanna" last="Cuomo">Giovanna Cuomo</name><affiliation wicri:level="1"><nlm:affiliation>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Division of Internal Medicine, Department of Medical and Surgical Sciences, "Luigi Vanvitelli" University of Campania, Piazza Miraglia, 3, 80138, Naples</wicri:regionArea><wicri:noRegion>Naples</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical rheumatology</title><idno type="eISSN">1434-9949</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Monoclonal, Humanized (pharmacology)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Arthritis, Rheumatoid (blood)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Complement C3 (metabolism)</term><term>Complement C4 (metabolism)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (pharmacologie)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Complément C3 (métabolisme)</term><term>Complément C4 (métabolisme)</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Polyarthrite rhumatoïde (sang)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Complement C3</term><term>Complement C4</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Complément C3</term><term>Complément C4</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Polyarthrite rhumatoïde</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Sujet âgé</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Tocilizumab, an anti-interleukin-6 receptor monoclonal antibody, is known to be able to rapidly reduce acute phase reactants. Although complement components are part of the acute phase, no data are available on a possible effect of tocilizumab on complement proteins. Serum levels of complement components C3 and C4 were retrospectively assessed in 19 consecutive rheumatoid arthritis patients eligible for tocilizumab treatment. Tocilizumab was found to reduce all known acute phase reactants, including C3 and C4 levels. C3 and C4 were found to decrease as early as 4 weeks after the first tocilizumab infusion. On average, C3 decreased by 24.02, 27.35, 33.62, and 32.81%, as compared to pre-treatment values, after 1, 3, 6, and 12 months of therapy, respectively; likewise, C4 decreased by 44.74, 43.40, 54.33, and 54.56% at the same time points with respect to pre-treatment values. A discrete proportion of patients (38.46 and 30.76% for C3 and C4, respectively) displayed subnormal complement serum levels early (4 weeks) after initiation of tocilizumab treatment, which raised suspicion for complement consumption. However, no circulating immunocomplexes were found nor did any patient ever display clinical features of immunocomplex disease during a median follow-up of 38 months. After 12 months of therapy, 68.75 and 56.25% of patients had abnormally low C3 and C4 serum levels, respectively. Reduction in C3 and C4 serum levels should be included among the anti-inflammatory effects exerted by tocilizumab and are thus to be considered as an expected outcome of the mechanism of action of this drug.</div></front></TEI><affiliations><list><country><li>Italie</li></country></list><tree><country name="Italie"><noRegion><name sortKey="Romano, Ciro" sort="Romano, Ciro" uniqKey="Romano C" first="Ciro" last="Romano">Ciro Romano</name></noRegion><name sortKey="Cuomo, Giovanna" sort="Cuomo, Giovanna" uniqKey="Cuomo G" first="Giovanna" last="Cuomo">Giovanna Cuomo</name><name sortKey="Del Mastro, Andrea" sort="Del Mastro, Andrea" uniqKey="Del Mastro A" first="Andrea" last="Del Mastro">Andrea Del Mastro</name><name sortKey="Esposito, Sergio" sort="Esposito, Sergio" uniqKey="Esposito S" first="Sergio" last="Esposito">Sergio Esposito</name><name sortKey="Sellitto, Ausilia" sort="Sellitto, Ausilia" uniqKey="Sellitto A" first="Ausilia" last="Sellitto">Ausilia Sellitto</name><name sortKey="Solaro, Eleonora" sort="Solaro, Eleonora" uniqKey="Solaro E" first="Eleonora" last="Solaro">Eleonora Solaro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001121 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001121 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29362962
|texte= Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29362962" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a TocilizumabV1
| This area was generated with Dilib version V0.6.34. |  |